KNSA FY 2019 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$3M

Operating Income

-$170M

Net Income

-$162M

EPS (Diluted)

$-2.99

Cash Flow

Operating Cash Flow

-$158M

Free Cash Flow

-$162M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$255M

Total Liabilities

$29M

Stockholders' Equity

$225M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$3M	-$286,000	-1046.5%
Operating Income	-$170M	-$108M	-57.1%
Net Income	-$162M	-$103M	-56.8%